Jayaram Sharan Chakkyath, Muzaffar Sayed Jameel, Ahmed Ikhlaaq, Dhanda Jagtar, Paleri Vinidh, Mehanna Hisham
Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, West Midlands, United Kingdom.
Head Neck. 2016 Dec;38(12):1855-1861. doi: 10.1002/hed.24531. Epub 2016 Jul 13.
Treatment of recurrent oropharyngeal cancer is widely thought to have poor outcomes. Justification for treatment, especially in advanced cases, can be difficult.
A systematic search of MEDLINE, Embase, and Cochrane databases was conducted. Included studies reported specific recurrent oropharyngeal cancer survival data.
Twenty-two retrospective studies were included. Pooled 3-year overall survival (OS) was 26% (95% confidence interval [CI] = 22% to 29%; I squared = 40.7%; p = .057). Pooled 5-year OS was 23% (95% CI = 20% to 27%; I squared = 73.9%; p = .000). Surgical treatment was superior to radiation (5-year OS 26% vs 16%, respectively; p < .001). The 5-year OS improved over time: 18% in the pre-2000 cohort; 35% in the mixed pre-2000 and post-2000 group; and 51% in the post-2000 cohort (p < .001).
Outcomes have improved considerably over the last 2 decades, resulting in approximately 50% overall 5-year survival. Human papillomavirus (HPV) status, patient selection, and improvements in care may explain this. © 2016 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck, 2016 © 2016 Wiley Periodicals, Inc. Head Neck 38: 1855-1861, 2016.
人们普遍认为复发性口咽癌的治疗效果不佳。尤其是在晚期病例中,治疗的合理性可能很难确定。
对MEDLINE、Embase和Cochrane数据库进行了系统检索。纳入的研究报告了特定复发性口咽癌的生存数据。
纳入了22项回顾性研究。汇总的3年总生存率(OS)为26%(95%置信区间[CI]=22%至29%;I²=40.7%;p=0.057)。汇总的5年总生存率为23%(95%CI=20%至27%;I²=73.9%;p=0.000)。手术治疗优于放疗(5年总生存率分别为26%和16%;p<0.001)。5年总生存率随时间推移有所提高:2000年前队列中为18%;2000年前和2000年后混合组中为35%;2000年后队列中为51%(p<0.001)。
在过去20年中,治疗结果有了显著改善,总体5年生存率约为50%。人乳头瘤病毒(HPV)状态、患者选择和治疗改善可能是其原因。©2016作者头颈外科由威利期刊公司出版。头颈外科,2016年©2016威利期刊公司。头颈外科38:1855 - 1861,2016年。